TP53 and osteosarcoma: Given that preceding research suggests that the p53 mutation is a key indicator and therapeutic target of osteosarcoma, the results from our study demonstrate the anticancer effects of colchicine, implying its clinical importance in osteosarcoma patients, regardless of p53 mutation.